Abstract
Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have